Article | November 7, 2022

Five Questions That Determine The Success Of Your PROTAC Programs

By Sachin Mangale, Product Marketing Lead – Discovery Services, Syngene International Ltd.

GettyImages-1169928112-patient-doctor-medicine-pill-capsule-tablet-OSD-oral

Proteolysis-targeting chimeras (PROTACs) and other protein degradation strategies are gaining increasing prominence due to the benefits they offer over small molecules in drug discovery for challenging targets. These include the ability of PROTAC molecules to selectively target proteins for degradation, their potential for sustained action, and low dosages required for degradation.

This blog article reviews five questions that need to be addressed when launching a PROTAC development program.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online